The publication reviews the results of 204 patients with 12 tumor types enrolled and treated on the eNRGy study, concluding "Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback